Deborah Ramsdell
Director Ejecutivo en Valerion Therapeutics LLC .
Perfil
Deborah Ramsdell is currently the President, Chief Executive Officer & Director at Valerion Therapeutics LLC.
She is also the President, Chief Executive Officer & Director at Phoenicis Therapeutics, Inc. Additionally, she holds the position of Director at Orphan Technologies Ltd.
and is the VP-Development Operations & Regulatory Affairs at Alopexx Enterprises LLC.
Ms. Ramsdell has previously worked as the President & Chief Executive Officer at Wings Therapeutics, Inc. She has also held positions as the Director-Regulatory Affairs & Quality Assurance at ImmunoGen, Inc. and Virus Research Institute, Inc. Furthermore, she has worked as the Principal at Biotechnica International, Inc. and as the VP-Regulatory Affairs & Clinical Operations at both Alexion Pharmaceuticals, Inc. and Enobia Pharma, Inc. Ms. Ramsdell completed her undergraduate and graduate degrees at Boston College.
Cargos activos de Deborah Ramsdell
Empresas | Cargo | Inicio |
---|---|---|
Valerion Therapeutics LLC
Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Valerion Therapeutics LLC develops targeted therapies for orphan genetic diseases. The firm utilizes a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a studied transport pathway. It therapies are based on an intracellular delivery technology platform that takes advantage of tissue targeting via an antibody and intracellular delivery dependent on membrane expression of a nucleoside transporter. The company was founded by Timothy S. Harris and Dustin D. Armstrong in 2007 and is headquartered in Concord, MA. | Director Ejecutivo | - |
Alopexx Enterprises LLC
Alopexx Enterprises LLC BiotechnologyHealth Technology Alopexx Enterprises LLC engages in investing and managing health care companies. It develops medical therapies and devices for infectious diseases, oncology, central nervous system, and orphan diseases. The firm commercializes an alternative for the treatment and prevention of staphylococcal and other bacterial infections and animal vaccines. The company was founded by Daniel R. Vlock, Deborah Ramsdell and Christine de los Reyes in 2011 and is headquartered in Concord, MA. | Consejero General | 01/01/2011 |
Orphan Technologies Ltd.
Orphan Technologies Ltd. Pharmaceuticals: MajorHealth Technology Orphan Technologies Ltd. engages in the manufacturing of biopharmaceutical drugs. It develops novel therapies for patients suffering from rare disorder and classical homocystinuria. The company is headquartered in Rapperswil, Switzerland. | Director/Miembro de la Junta | 01/02/2015 |
Phoenicis Therapeutics, Inc.
Phoenicis Therapeutics, Inc. BiotechnologyHealth Technology Phoenicis Therapeutics, Inc. is a private company that is focused on developing therapies for rare dermatological disorders. The company is based in Hingham, MA. The company's goal is to improve the lives of those who suffer from these conditions. The CEO of the company is Deborah Ramsdell. | Director Ejecutivo | - |
Antiguos cargos conocidos de Deborah Ramsdell.
Empresas | Cargo | Fin |
---|---|---|
Wings Therapeutics, Inc.
Wings Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Wings Therapeutics, Inc. engages in the development of transformational therapies for patients that suffer from Dystrophic Epidermolysis Bullosa. The company was founded in 2019 and is headquartered in Berkeley, CA. | Director Ejecutivo | - |
ALEXION PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | - |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Consejero General | - |
Biotechnica International, Inc.
Biotechnica International, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Groupe Limagrain Holding SA, Biotechnica International, Inc. is a company that specializes in agricultural research. The company is based in Shawnee Mission, KS. | Corporate Officer/Principal | - |
IMMUNOGEN, INC. | Consejero General | - |
Formación de Deborah Ramsdell.
Boston College | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 10 |
---|---|
Biotechnica International, Inc.
Biotechnica International, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Groupe Limagrain Holding SA, Biotechnica International, Inc. is a company that specializes in agricultural research. The company is based in Shawnee Mission, KS. | Commercial Services |
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Virus Research Institute, Inc.
Virus Research Institute, Inc. BiotechnologyHealth Technology Part of Celldex Therapeutics, Inc., Virus Research Institute, Inc. develops systems for the delivery of vaccines. The company is based in Cambridge, MA. | Health Technology |
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
Valerion Therapeutics LLC
Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Valerion Therapeutics LLC develops targeted therapies for orphan genetic diseases. The firm utilizes a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a studied transport pathway. It therapies are based on an intracellular delivery technology platform that takes advantage of tissue targeting via an antibody and intracellular delivery dependent on membrane expression of a nucleoside transporter. The company was founded by Timothy S. Harris and Dustin D. Armstrong in 2007 and is headquartered in Concord, MA. | Health Technology |
Alopexx Enterprises LLC
Alopexx Enterprises LLC BiotechnologyHealth Technology Alopexx Enterprises LLC engages in investing and managing health care companies. It develops medical therapies and devices for infectious diseases, oncology, central nervous system, and orphan diseases. The firm commercializes an alternative for the treatment and prevention of staphylococcal and other bacterial infections and animal vaccines. The company was founded by Daniel R. Vlock, Deborah Ramsdell and Christine de los Reyes in 2011 and is headquartered in Concord, MA. | Health Technology |
Orphan Technologies Ltd.
Orphan Technologies Ltd. Pharmaceuticals: MajorHealth Technology Orphan Technologies Ltd. engages in the manufacturing of biopharmaceutical drugs. It develops novel therapies for patients suffering from rare disorder and classical homocystinuria. The company is headquartered in Rapperswil, Switzerland. | Health Technology |
Wings Therapeutics, Inc.
Wings Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Wings Therapeutics, Inc. engages in the development of transformational therapies for patients that suffer from Dystrophic Epidermolysis Bullosa. The company was founded in 2019 and is headquartered in Berkeley, CA. | Health Technology |
Phoenicis Therapeutics, Inc.
Phoenicis Therapeutics, Inc. BiotechnologyHealth Technology Phoenicis Therapeutics, Inc. is a private company that is focused on developing therapies for rare dermatological disorders. The company is based in Hingham, MA. The company's goal is to improve the lives of those who suffer from these conditions. The CEO of the company is Deborah Ramsdell. | Health Technology |
- Bolsa de valores
- Insiders
- Deborah Ramsdell